Nektar Therapeutics Posts Lower Revenue and Wider Losses Across Both Reporting Windows

Bottom line

- NEKTAR THERAPEUTICS filed a Quarterly Report on Form 10-Q for the three-month reporting period and the six-month year-to-date period, identified by 0001193125-26-349805 and 0000906709, trading as NKTR. The fiscal period covered by this filing is period-ended-2026-06-30, and the comparative prior-year windows are referenced as the three months ended June 30, 2025 and the six months ended June 30, 2025 against the current the three months ended June 30, 2026 and the six months ended June 30, 2026.

- For the three-month reporting period, Revenue from Contract with Customer, Excluding Assessed Tax was $10,131,000 USD, lower than the prior-year comparative of $11,175,000 USD. Operating Income (Loss) was -$42,341,000 USD, wider than the prior-year loss of -$36,230,000 USD. Net Income (Loss) Attributable to Parent was -$40,622,000 USD, an increase relative to the prior-year loss of -$41,593,000 USD, with the transition moving loss to loss.

- For the six-month year-to-date period, Revenue from Contract with Customer, Excluding Assessed Tax was $20,992,000 USD, lower than the prior-year comparative of $21,635,000 USD. Operating Income (Loss) was -$81,395,000 USD, wider than the prior-year loss of -$80,765,000 USD. Net Income (Loss) Attributable to Parent was -$85,526,000 USD, an increase relative to the prior-year loss of -$92,475,000 USD, with the transition moving loss to loss. Earnings Per Share, Diluted for the six-month year-to-date period was -$2.96 per diluted share USD/SHARES, an increase relative to the prior-year loss per share of -$6.57 per diluted share USD/SHARES.

- The filing evidence does not attribute this change to any single cause.

- The filing evidence contains no peer or industry comparison.

- The filing evidence does not disclose segment-level detail for this dimension.

- The source scope for this analysis is the Quarterly Report on Form 10-Q filed by NEKTAR THERAPEUTICS under 0001193125-26-349805, drawing on the financial statements presented in Part I and the disclosures in Part II items Item 1, Item 1A, Item 2, Item 3, Item 4, Item 5, and Item 6, together with the accounting policy and related-party notes cited as Note 1, Note 4, and Note 6. The clinical-trial references Phase 2 and Phase 3 are available in the filing for context on rezpegaldesleukin development but are not used to support financial claims in this section.

- Readers comparing this clinical-stage biotechnology loss profile against diversified peers can cross-check the directional pattern in a REINSURANCE GROUP OF AMERICA INC Filing for contrast, while another pre-revenue biotech with losses on both windows is discussed in the Oruka Therapeutics interim filing analysis. A complementary reading tool is offered at ROI Calculator.

Financial performance

- NEKTAR THERAPEUTICS reported under 10-Q for period-ended-2026-06-30 (accession 0001193125-26-349805, CIK 0000906709, ticker NKTR) on the three-month window the three months ended June 30, 2026 and the six-month window the six months ended June 30, 2026. - Reported facts (top-line and operating loss): for the six months ended June 30, 2026, revenue was $20,992,000 USD and operating loss was -$81,395,000 USD; for the three months ended June 30, 2026, revenue was $10,131,000 USD and operating loss was -$42,341,000 USD.

Prior comparatives are $21,635,000, -$80,765,000, $11,175,000, and -$36,230,000 USD. - Reported facts (bottom-line and per-share loss): net loss attributable to parent was -$85,526,000 USD for the six months ended June 30, 2026 and -$40,622,000 USD for the three months ended June 30, 2026, versus -$92,475,000 and -$41,593,000 USD in the prior windows. 57 per diluted share USD/SHARES for the six months ended June 30, 2025.

- YOY: revenue moved lower on both windows (a decrease in the six months ended June 30, 2026 versus the six months ended June 30, 2025 and a decrease in the three months ended June 30, 2026 versus the three months ended June 30, 2025); operating loss widened on both windows (a decrease in the six months ended June 30, 2026 versus the six months ended June 30, 2025 and a decrease in the three months ended June 30, 2026 versus the three months ended June 30, 2025); the bottom-line net loss narrowed on both windows (an increase in the six months ended June 30, 2026 versus the six months ended June 30, 2025 and an increase in the three months ended June 30, 2026 versus the three months ended June 30, 2025, loss to loss in each case); and diluted EPS moved from one negative reading to a less negative reading across the six-month comparison (loss to loss, increase).

- QOQ: the three-month revenue figure is presented alongside the six-month figure only on a year-over-year basis in this filing; the filing does not present a sequential three-month-versus-prior-three-month pair on the the three months ended June 30, 2026 basis in the claim set, so any quarter-on-quarter movement is not derivable from the supported facts. - Accounting context: the report is prepared in accordance with Note 1 (Organization and Summary of Significant Accounting Policies) and the unaudited condensed disclosure framework described in the cited note, with related-party disclosures referenced in Note 4.

Item 1A frames the risk-factor discussion, Item 4 covers controls and procedures, and Item 3 covers market-risk disclosures; none of those referenced items contributes a quarter-on-quarter or segment-level datapoint to this section. - Segment detail is not separately presented on the lines used here: The filing evidence does not disclose segment-level detail for this dimension.. - Management explanation versus analyst inference: management characterises the company as a clinical-stage biopharmaceutical with substantial ongoing research and development obligations and concentrated reliance on the rezpegaldesleukin program (clinical activity referenced in Phase 2 and Phase 3); the filing explicitly flags a substantial net loss from operations.

The link between that commentary and the specific revenue or operating-loss movement on either window is not stated in the filing evidence, so any attribution is The filing evidence does not attribute this change to any single cause.. - Peer comparison: the filing evidence contains no peer or industry comparison; that absence is captured by The filing evidence contains no peer or industry comparison.. - Counter-evidence and unknowns: nothing in the claim set contradicts the year-over-year revenue and operating-loss direction above, but the magnitude and the per-share comparisons are the only quantitative anchors supplied; segment-level splits, sequential quarter-on-quarter revenue, and any forward guidance for upcoming periods are not disclosed on the supported fact keys for this section.

Operating drivers and segments

- The filing reports a single operating segment, consistent with the consolidated income-statement presentation and the absence of any separately disclosed segment grouping in the cited notes. - Reported Revenue from Contract with Customer, Excluding Assessed Tax for the three months ended June 30, 2026 was $10,131,000 USD, which the catalog records as lower than the prior-year comparative $11,175,000 USD; both values are positive in direction, and the authorized comparison frames the current period as a decrease against the prior year. - Reported Revenue from Contract with Customer, Excluding Assessed Tax for the six months ended June 30, 2026 was $20,992,000 USD, also lower than the prior-year comparative $21,635,000 USD; the authorized comparison characterizes the year-to-date window as a decrease against the prior year as well. - Reported Operating Income (Loss) for the three months ended June 30, 2026 was -$42,341,000 USD, a loss, deeper than the prior-year comparative -$36,230,000 USD, which was also a loss; the authorized comparison records a decrease relative to the prior year. - Reported Operating Income (Loss) for the six months ended June 30, 2026 was -$81,395,000 USD, a loss, deeper than the prior-year comparative -$80,765,000 USD, which was also a loss; the authorized comparison again records a decrease. - Margin commentary is not separately tabulated in the filing: revenue and operating loss are presented only at the consolidated level, with no gross-margin or per-program margin disclosed in the cited notes.

- Management frames the quarter around a clinical pipeline narrative rather than a near-term commercial one, calling out the Phase 2 program in moderate-to-severe atopic dermatitis and the Phase 3 ZENITH-AD program in patients across the cited age range, and links forward-looking statements to the broader pipeline described in Item 1A and the forward-looking legend above it. - Management reiterates that forward-looking statements speak as of the filing date and are subject to the risk factors set out under Item 1A and the cautionary language that follows the forward-looking legend, without attributing the quarter or year-to-date revenue and operating-loss direction to any single operational driver. - The accounting-policy disclosures referenced through Note 1 and Note 6 address presentation, consolidation, and the ASU referenced in Item 3, and the related-party note Note 4 surfaces a Gannet BioChem relationship that the filing flags separately from the operating results. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - Readers comparing clinical-stage biotech filings may also find the contrasting depth-of-loss picture in Oruka Therapeutics Interim Filing Shows Deepening Losses on Both Windows useful as a peer-frame, though no peer benchmark is contained in the filing evidence for NEKTAR THERAPEUTICS.

Cash flow and capital

The reported cash and cash equivalents balance at the balance sheet date stood at $39,267,000 USD, while current accounts payable were $24,891,000 USD as of the balance sheet date of June 30, 2026. Accounts payable is reported as a current liability and reflects amounts owed to vendors and service providers in the ordinary course. The cash balance is the headline liquidity figure on the balance sheet and underpins the management statement that the company has sufficient resources to fund operations through at least the next twelve months from the filing date.

For the six-month year-to-date period, net cash used in operating activities was -$120,068,000 USD, compared with -$94,791,000 USD used in the prior-year comparative period, an authorized decrease. Both periods show operating cash outflows, consistent with a clinical-stage biopharmaceutical company that has not yet reached sustainable recurring revenue. Net cash provided by investing activities was -$749,899,000 USD for the current six-month period, compared with $93,304,000 USD in the prior-year period, an authorized decrease from positive to negative. Net cash provided by financing activities was $894,118,000 USD for the current six-month period versus $218,000 USD in the prior-year period, an authorized increase.

Capital expenditures, presented as payments to acquire property, plant, and equipment, were $112,000 USD for the six-month period, compared with $39,000 USD in the prior-year six-month period, an authorized increase. The cited level of capital spending is modest in absolute terms and consistent with a research and development-focused operating model rather than a build-out of large-scale manufacturing capacity.

Management explains the operating cash burn as a function of continued research and development activities and the expectation of further substantial losses and negative operating cash flows. The company states it has financed operations primarily through public and private placements of debt and equity securities, royalties and product sales, and upfront and milestone payments under strategic collaboration agreements. Management explicitly anticipates that additional cash will be needed as research and development continues and signals openness to new collaboration agreements or dilutive equity-based financings, including a potential offering of common stock. The related-party disclosure in Note 4 ties balance sheet and statement-of-operations entries to transactions with Gannet BioChem, and Note 1 covers organization and summary of significant accounting policies that frame the cash and payable presentation.

From an analyst perspective, the combination of negative operating cash flow, positive financing cash flow, and a shift in investing cash flow reads as a company drawing on capital markets to fund ongoing clinical work, including the programs referenced in Phase 2 and Phase 3. Capital expenditures remain small relative to the operating cash outflow. Counter-evidence within the filing to a tight liquidity story is limited: management asserts a twelve-month operating runway from the filing date, and the cash balance is the only on-balance-sheet liquidity figure in the catalog. Reader-relevant context on interim reporting volatility is set out in Item 3 and Item 4. Unknowns remain around the timing and size of any future dilutive financing and the precise split of operating cash burn between research and development and general and administrative outflows.

Peer and historical context

- The filing itself supplies a structured set of year-over-year comparisons for revenue, operating loss, net loss, and operating cash flow, but it supplies nothing analogous about competitors in the same therapeutic space, so the analyst is limited to a self-versus-self frame. - The directional moves embedded in the authorized comparisons are the only ones a reader can rely on; cause language, peer benchmarking, and industry commentary cannot be layered on without overstating the source.

- The prior-year revenue figures for both the three-month and six-month windows are themselves positive, which means the revenue decline is occurring off a non-zero base rather than a wind-down — a nuance that a generic "down year-over-year" statement would obscure. - Operating cash flow was negative in both the prior and current six-month periods, and the authorized direction is a decrease; combined with continued operating losses, this suggests the cash burn quickened even though the prior-year column was already an outflow, not a baseline profit.

- Across the current three-month window, revenue moved lower than the prior-year three-month window, while net loss moved higher (that is, the loss narrowed less than the prior year, or the absolute loss figure moved in the direction the catalog calls "increase" for a loss line) and operating loss also moved higher on the same convention; net loss stayed a loss, and operating loss stayed a loss, so the transition in both cases is loss-to-loss rather than a swing to profitability. - Across the six-month year-to-date window, revenue again moved lower than the prior-year six-month window, while net loss and operating loss both moved higher on the catalog's loss-line convention and remained losses; the transition is loss-to-loss on both lines, mirroring the quarterly pattern. - Net cash used in operating activities was negative in both six-month windows, with the authorized direction being a decrease (greater outflow) in the current period, which is consistent with the wider operating loss and with the company's stated reliance on contract manufacturers and on its investment portfolio — both of which the filing flags as concentration risks but does not quantify against a peer set. - The filing's own commentary emphasises interim variability and cautions that the second-quarter results "are not necessarily indicative of the results to be expected for the full year," which itself is a counterweight to any read that treats the half-year deterioration as a steady-state trend. - Related-party disclosures tied to Gannet BioChem and the available-for-sale concentration in banking and financial-services issuers are surfaced in the cited note, but the filing does not pair these items with peer benchmarks, so the reader cannot test them against industry medians or against other mid-cap clinical-stage developers using this document alone. - Where peer benchmarking would normally appear, the filing offers no comparator set; readers comparing Nektar Therapeutics against the Oruka Therapeutics interim filing that also shows deepening losses on both windows should treat that cross-reference as illustrative only, since the two companies are not framed as peers inside this filing.

Scenario analysis

- In the base case for NEKTAR THERAPEUTICS (NKTR), the headline picture from the 10-Q for period-ended-2026-06-30 is a wider top line and a wider bottom line, and that combination is the analytical anchor for everything that follows. - Reported reality: revenue came in at $10,131,000 for the three months ended June 30, 2026, against $11,175,000 for the three months ended June 30, 2025; on the six-month window, revenue was $20,992,000 for the six months ended June 30, 2026, against $21,635,000 for the six months ended June 30, 2025.

The authorized comparison calls this a decrease on both windows, so the top-line story for the base scenario is softer collaboration and licensing receipts. - On profitability, the authorized comparison shows net loss moving from loss to loss with a worsening gap: the period produced -$40,622,000 versus -$41,593,000 on the three-month view, and -$85,526,000 versus -$92,475,000 on the year-to-date view. The base scenario therefore layers a contracting revenue base on top of an expanding net loss, even before considering operating costs.

- Upside scenario: if rezpegaldesleukin moves through the next data inflection points — the Phase 2 program in moderate-to-severe atopic dermatitis and the Phase 3 AD program cited in the filing — without renewed setbacks, management could frame a story where collaboration receipts stabilize, R&D burn plateaus, and the net-loss direction turns from worse to better. The companion comparator REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing is useful only as a structural reminder that an interim filing showing both revenue growth and net income expansion is the kind of pattern Nektar would need to approximate to validate an upside path; nothing in the current filing supports that pattern, but the lane is described.

- Downside scenario: the wider gap between revenue and net loss, combined with the concentration disclosures in the cited note (single-source contract manufacturers and significant banking-sector exposure in available-for-sale securities), leaves a downside lane in which a credit event or a manufacturing disruption compounds an already weakening top line. The filing evidence does not attribute this change to any single cause. - Counter-evidence and unknowns that should bracket any conditional reading: - The filing does not provide a forward revenue trajectory, milestone schedule, or probability-weighted cash forecast, so the upside and downside scenarios cannot be sized — they are qualitative lanes rather than probabilities.

- The cited note flags Gannet BioChem related-party transactions under Note 4; the magnitude and any embedded pricing effect on reported revenue and expense are not quantified in the visible text. - The cited references Item 1 through Item 6 supply legal-proceedings, risk-factor, controls, and market-risk context that may reshape any lane, but the body of the filing reviewed here does not surface a specific legal matter or new risk-factor that would, on its own, swing the base scenario into either side. - The filing evidence contains no peer or industry comparison.

- Reading guidance: treat the base scenario as the working case until rezpegaldesleukin data or partnership economics move one of the lanes; treat upside and downside as conditional scaffolds rather than forecasts, because the filing does not yet support quantification on either side.

Risks and what to watch

- The reported figures from NEKTAR THERAPEUTICS (NKTR) in this 10-Q for period-ended-2026-06-30 (accession 0001193125-26-349805, CIK 0000906709) frame a narrow set of risk surfaces worth carrying into the next filing window.

Reported facts (this period and the prior-year comparative windows): - Net Income (Loss) Attributable to Parent for the three-month reporting period (the three months ended June 30, 2026) was -$40,622,000, compared with -$41,593,000 for the three months ended June 30, 2025. The authorized direction shows the current-period loss moving from a loss to a loss, with the authorized relation indicating the change. - Net Income (Loss) Attributable to Parent for the six-month year-to-date period (the six months ended June 30, 2026) was -$85,526,000, compared with -$92,475,000 for the six months ended June 30, 2025 — again a loss in both windows, with the authorized direction likewise framing the transition loss to loss and the authorized relation indicating the change. - Revenue from Contract with Customer, Excluding Assessed Tax for the three-month reporting period (the three months ended June 30, 2026) was $10,131,000, compared with $11,175,000 for the three months ended June 30, 2025 — positive in both windows, with the authorized direction showing the current-period revenue as smaller. - Revenue from Contract with Customer, Excluding Assessed Tax for the six-month year-to-date period (the six months ended June 30, 2026) was $20,992,000, compared with $21,635,000 for the six months ended June 30, 2025 — positive in both windows, with the authorized direction also showing the current-period revenue as smaller.

Management explanations: - Management flags significant concentrations in the supply chain, noting reliance on contract manufacturers — including a single contract manufacturer in certain cases — for raw materials, manufacturing, and other development services, with any delay or interruption framed as capable of materially affecting business, financial condition, and results of operations. (Per the cited note on Significant Concentrations.) - Management likewise flags concentration in available-for-sale securities within the banking and financial services industries, noting that issuer downgrades below the minimum credit rating could force sales and crystallize losses on those securities. (Per the cited note on Significant Concentrations.) - Management describes the net loss per share methodology, noting that pre-funded warrants are treated as outstanding for basic loss per share, and that basic and diluted are identical across the three- and six-month periods presented. (Per the cited note on Net Loss Per Share.) - Management indicates the Company is currently evaluating the incremental disclosures required under the recently issued FASB expense-disaggregation update. (Per the cited note on the relevant accounting standard update.)

Analyst inference (constrained to the authorized comparisons): - The combination of a moving loss on both the quarter and the half-year, together with lower revenue on both windows, narrows the set of plausible explanations the filing invites the reader to consider — namely partnership-economics timing on revenue (per Note 1 and the related-party note referenced as Note 4) and clinical-development spend against the Phase 2 and Phase 3 rezpegaldesleukin programs. - The risk-factor discussion sits in Item 1A and the legal-proceedings and other-information context sits in Item 1, while controls and procedures appear in Item 4, market-risk disclosures in Item 3, unregistered-sales context in Item 2, and exhibits and forward-looking statements in Item 6 and the closing block referenced via Item 5.

Counter-evidence and unknowns: - The filing does not provide peer or industry benchmarks against which to size the revenue decline or the loss widening. The filing evidence contains no peer or industry comparison. - The filing evidence does not attribute this change to any single cause. - The filing does not disclose the timing or probability of any partnership milestone that might reverse the revenue direction, nor the cadence of any clinical read-outs from the Phase 2 or Phase 3 programs in the next window.

Metrics to watch next period: - Revenue trajectory on both the three-month and six-month windows, especially any milestone or collaboration recognition that could break the current lower-revenue pattern — a pattern also visible in peers profiled in adjacent filings, such as the Oruka Therapeutics interim filing on deepening losses. - Loss trajectory on both windows, particularly the gap between operating loss and net loss and any swing in non-operating items tied to the available-for-sale securities book. - Cash-use sustainability, given the concentration disclosures on both the manufacturer side and the investment-portfolio issuer side. - Incremental disclosure footprint from the FASB expense-disaggregation update, which management is still evaluating.